External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population
External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population
复制标题
DOI：
10.1016/j.urology.2006.10.022
复制
发表时间：
2006-12-01
期刊：
影响因子：
2.1
通讯作者：
Thompson, Ian M.
中科院分区：
文献类型：
--
作者：
Parekh, Dipen J.;Ankerst, Donna Pauler;Thompson, Ian M.
目标。旨在评估早期检测研究网络的圣安东尼奥前列腺癌风险生物标志物中心 (SABOR) 队列中最近开发的前列腺癌预防试验 (PCPT) 前列腺癌风险计算器，该队列比 PCPT 中的队列更年轻、种族更多样化。方法。从 3488 名 SABOR 参与者中，我们确定了 446 名接受过前列腺活检并在活检前接受过前列腺特异性抗原测量和直肠指检的人。大多数活检是针对直肠指检异常、前列腺特异性抗原水平超过 2.5 ng/mL 或因一级亲属患有前列腺癌而导致风险升高而进行的。我们评估了 PCPT 计算器在 SABOR 参与者队列中检测前列腺癌的操作特性。在该队列的 446 名男性中，24% 年龄低于 55 岁。结果。在 446 名接受活检的男性中，148 名 (33.2%) 患有前列腺癌。观察到的 SABOR 前列腺癌发生率随着 PCPT 风险的增加而增加：PCPT 风险计算器值小于 25%、25% 至 50%、50% 至 75% 和大于 75% 时，分别为 15.7%、39.0%、48.8% 和 100.0%。 PCPT 风险计算器的受试者工作特征曲线下面积为 65.5%（95% 置信区间为 60.2% 至 70.8%，P < 0.0001），非洲裔美国男性的 PCPT 风险计算器（曲线下面积为 80.0%，95% 置信区间为 67.8% 至 92.2%）高于其他种族 (P = 0.02)，并且在西班牙裔男性中没有差异(P > 0.05)。结论。我们的研究结果表明，PCPT 风险计算器（可从互联网上获取并包含当前最佳的风险因素组）对于其他更多样化的人群也有效。
Objectives. To evaluate the recently developed Prostate Cancer Prevention Trial (PCPT) prostate cancer risk calculator in the San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR) cohort of the Early Detection Research Network, a younger and more ethnically diverse population than that in the PCPT.Methods. From 3488 SABOR participants, we identified 446 who had undergone prostate biopsy and had undergone prostate-specific antigen measurement and digital rectal examination before biopsy. Most biopsies were performed for abnormal digital rectal examination findings, a prostate-specific antigen level of more than 2.5 ng/mL, or elevated risk because of a first-degree relative with prostate cancer. We evaluated the operating characteristics of the PCPT calculator for detecting prostate cancer in this cohort of SABOR participants. Of the 446 men in this cohort, 24% were younger than 55 years of age.Results. Of the 446 men who had undergone biopsy, 148 (33.2%) had prostate cancer. The observed SABOR prostate cancer rates increased with increasing PCPT risk: 15.7%, 39.0%, 48.8%, and 100.0% for a PCPT risk calculator value of less than 25%, 25% to 50%, 50% to 75%, and greater than 75%, respectively. The PCPT risk calculator had an area under the receiver operating characteristic curve of 65.5% (95% confidence interval 60.2% to 70.8%, P < 0.0001), was greater in African-American men (area under curve of 80.0%, 95% confidence interval 67.8% to 92.2%) than in other races (P = 0.02), and was not different in Hispanic men (P > 0.05).Conclusions. The results of our study have shown that the PCPT risk calculator, available from the Internet and incorporating the current best panel of risk factors, is valid in other, more diverse, populations.